Benjamin McEnroe

Benjamin received his Bachelor of Science (Hons) from the University of Queensland, undertaken within the Translation Cancer Immunotherapy (TCI) lab at the Queensland Institute for Medical Research (QIMR). While a student at QIMR, his work focused on further characterizing and targeting a CD19 transcript variant identified in patients resistant to CD19 directed CAR-T therapy. In 2019, Benjamin stayed on in the TCI as a research assistant. Through his scientific experience, Ben honed various flow cytometry, molecular cloning and mouse handling procedures. He joined the Bald Lab in 2021 as a PhD student to explore the underlying mechanisms of the co-stimulatory molecule CD226 in both conventional CD8+T cell and CAR-T cell activation. This work will involve establishing a novel nanobody based CAR-T cell platform.